Hospital systems and nonprofits are looking for ways to reach patients virtually as face-to-face interactions continue to be limited due to the coronavirus. Getty Images

Hospitals across the country are trying their best to limit the number of people coming in and out — but how does that affect patients in need of non-COVID-19 treatment? Hospital systems are implementing new technology and training so that physicians can use telemedicine to connect virtually.

In March following telemedicine training, Houston Methodist began seeing hundreds more daily telemedicine sessions across its system, Josh Sol, administrative director of Innovation and Ambulatory Clinical Systems at Houston Methodist, previously told InnovationMap. And other hospital systems are following suit.

HCA Houston Healthcare's CareNow locations have implemented Virtual Care, a telehealth urgent care service. Patients can check in online during the urgent care center's operating hours to gain one-on-one access to care from a CareNow physician, nurse practitioner, or physician assistant. Providers, via video chat, will evaluate minor conditions and can prescribe non-narcotic medications when indicated.

If the situation calls for it, providers will tell the patient to come onsite to continue care.

"Virtual Care is an extension of our clinical urgent care services and fully supports our purpose to help people return to what they value in their lives, in an even more convenient way. We are proud to provide an easy solution for our patients' healthcare needs at their fingertips," says Dr. Mujtaba Ali-Khan, chief medical officer for HCA Houston Healthcare, in a news release.

Dallas-based CareNow was acquired by HCA in 2015 and has 16 locations in the greater Houston area.

Health care nonprofits are also taking advantage of remote ways to reach patients. Houston-based nonprofit CanCare is in the business of supporting cancer patients and their families and, despite a global pandemic, has not let up on its services to those in need. In fact, cancer patients with their weakened immune system are at greater risk of developing COVID-19 and are in need more than ever of CanCare's one-on-one matching emotional support service.

"The cancer community is in our thoughts and prayers during this time of uncertainty," says CanCare's President and CEO Cristina Vetrano in a news release. "Now more than ever, the community needs the help of our volunteers and support services. Our mission is not only to ensure the safety of clients, patients and caregivers but also to assure the community that they will continue to receive support throughout this challenging time."

Cancer patients can reach support via email at support@cancare.org or by calling the support line support line at 713-364-1652.

The Houston health care ecosystem will continue to see advances in telemedicine and remote care. One Houston startup, Medical Informatics, has created a virtual ICU program, called Sickbay, and the tech tool is being used to remotely monitor patients in Houston Methodist. The program works around the clock from a control hub to use artificial intelligence and algorithms to monitor patients.

"We designed our Sickbay platform to give lost data back to doctors, nurses and other members of the care team so they could save more lives," says Vincent Gagne, vice president of product for MIC, in a news release.

As the world emerges from COVID-19 — whenever and however that happens — telemedicine will have advanced as a viable option for physicians in a quicker way than it would have otherwise, Sol says.

"Telemedicine is here to stay now with the rapid adoption that just happened," he says. "The landscape will change tremendously."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.